438O Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
作者
K. Park,Fabrice Barlési,F. Ciardiello,Joachim von Pawel,S. Gadgeel,T. Hida,D. Kowalski,M.A. Cobo Dols,Diego Luigi Cortinovis,J. Leach,Jonathan A. Polikoff,David R. Gandara,C. Barrios,Daniel S. Chen,Pei He,Marcin Kowanetz,M. Ballinger,Daniel Waterkamp,Alan B. Sandler,A. Rittmeyer